J Cancer 2021; 12(17):5241-5248. doi:10.7150/jca.48989 This issue

Review

Gasdermin E-mediated programmed cell death: An unpaved path to tumor suppression

Yueyuan Wang1, Jingyu Peng1, Xiao Xie1, Zhihao Zhang1, Mingxi Li2, Ming Yang1✉

1. Department of Breast Surgery, The First Hospital of Jilin University, Changchun, People's Republic of China.
2. Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, People's Republic of China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Wang Y, Peng J, Xie X, Zhang Z, Li M, Yang M. Gasdermin E-mediated programmed cell death: An unpaved path to tumor suppression. J Cancer 2021; 12(17):5241-5248. doi:10.7150/jca.48989. Available from https://www.jcancer.org/v12p5241.htm

File import instruction

Abstract

Graphic abstract

Hearing loss-associated protein gasdermin E (GSDME), an effector of secondary necrosis, has been identified in a new pathway of programmed cell death (PCD). GSDME epigenetic silencing and mutations resulting in loss-of-function have been reported in cancer tissues. Additionally, GSDME upregulation inhibits tumor proliferation as well as colony forming ability, and reduces the incidence of lymphatic metastasis, demonstrating that GSDME may act as a tumor suppressor. Here, we have focused on the molecular mechanisms of GSDME-mediated PCD, and tried to reveal the crosstalk between this cell death pathway and apoptosis, autophagy, GSDMD-mediated pyroptosis. Moreover, we concluded the anti-cancer activity of GSDME include forming permeable membranes, and triggering anti-cancer immunity. Thus, GSDME was potential to be a novel target for cancer prevention and treatment.

Keywords: GSDME, programmed cell death, cancer, immunity